Cancer drug candidate unveiled, could start human trials in 2022

A new cancer drug under development could begin Phase 1 testing in humans in 2022 after it obtained good results in treating eight types of cancers in tests on animals, Taiwan's National National Health Research Institutes (NHRI) announced Monday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)